ZNL-0056 is an orally active ATP-competitive inhibitor that targets the EGFR ATP-binding site, specifically Cys797 and Cys775. It selectively inhibits EGFR and its downstream signaling in H3255 cells. ZNL-0056 is applicable for cancer research.
Target-Kategorie:
EGFR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
